Ibogaine-Associated Psychosis in Schizophrenia: A Case Report

Houenou, Josselin, Homri, Wided, Leboyer, Marion, Drancourt, Noémie · 2011 · Journal of Clinical Psychopharmacology

AI-extracted · unverified · confirm at source

First report of ibogaine-associated psychosis in schizophrenia; recommends excluding schizophrenia from ibogaine trials and screening for ibogaine use in shamanic-ritual psychosis

Dosing: unquantified (Iboga powder, small amounts escalating to daily use over 2 months) (oral)

Sample size: 1

Contraindications: Schizophrenia or psychotic disorders, Attenuated psychotic symptoms or prodromal psychosis, Active psychosis, Unsupervised consumption outside clinical setting, Daily or chronic ibogaine use